ArokaGO
  • Community

Company

ArokaGO

Your trusted medical tourism platform. Connect with world-class healthcare providers in Thailand.

Apple StoreGoogle Play
FacebookInstagramYouTubeTikTokLinkedInRahu

For Patients

  • Dashboard
  • Search Providers
  • Login
  • Register as Patient
  • Book Appointment

For Providers

  • Dashboard
  • Appointments
  • Chat
  • Login
  • Join as Provider

Contact Us

  • Bangkok, Thailand
  • +66 65 829 4562
  • contact@arokago.com

Legal

  • Disclaimer
  • Privacy Policy
  • Review Policy
  • Advertising

© 2026 ArokaGO. All rights reserved.

New COVID-19 Variant “Cicada” (BA.3.2) Under Global Watch as Cases Spread Across Multiple Countries
  1. /
  2. News
  3. /
  4. Global Health News
2 min read
|
March 28, 2026

New COVID-19 Variant “Cicada” (BA.3.2) Under Global Watch as Cases Spread Across Multiple Countries

Global Health Desk   Health authorities worldwide are closely monitoring a newly emerging COVID-19 variant known as “Cicada” (BA.3.2), as early data suggests a high number of mutations and increasing international spread.

Share this news
T
The ArokaGO Reporter
Global Health News
T
The ArokaGO Reporter
Global Health News

Global Health Desk   Health authorities worldwide are closely monitoring a newly emerging COVID-19 variant known as “Cicada” (BA.3.2), as early data suggests a high number of mutations and increasing international spread.

 

The variant, first identified in 2024 but previously detected at low levels, has recently re-emerged and is now being reported in at least 20 countries, including Japan, United Kingdom, and Netherlands. In some regions, it is estimated to account for up to 30% of detected cases.

 

The Centers for Disease Control and Prevention (CDC) stated in a recent update that it is tracking the spread of BA.3.2, following a gradual increase in infections within the United States. Meanwhile, the World Health Organization has classified the variant as one under monitoring since February, reflecting concerns over its evolving characteristics.

 

Experts note that BA.3.2 carries a significantly higher number of mutations estimated at around 70 to 75 compared to earlier variants such as JN.1. This raises the possibility that the variant could partially evade immunity from prior infection or vaccination, although further research is still ongoing.

 

Despite these concerns, BA.3.2 currently represents a relatively small proportion of cases in the United States, accounting for approximately 3.7% of sampled infections. However, epidemiologists caution that the variant could gain dominance if transmission continues to accelerate.

 

In terms of symptoms, early observations suggest that infections caused by the Cicada variant are broadly similar to other COVID-19 strains. Common symptoms include runny or blocked nose, headache, fatigue, sneezing, sore throat, and cough, as well as changes in taste or smell.

 

Some reports have also noted cases of unusually severe sore throat, described by patients as a sharp or cutting sensation, which appears to be more frequently associated with newer variants.

 

While there is currently no clear evidence that BA.3.2 leads to more severe illness, public health experts warn that declining vaccination rates and relaxed preventive measures in many countries could increase the risk of renewed outbreaks.

 

Authorities continue to emphasize the importance of surveillance, vaccination, and public awareness as key tools in managing potential future waves of infection.

 

 

Source : USAtoday

T
The ArokaGO Reporter
Global Health News

Articles in this category are written by our editorial team to keep you informed about the latest healthcare and medical tourism news.

More News

New Zealand Alcohol Consumption Falls to Record Low in 2025
Previous

New Zealand Alcohol Consumption Falls to Record Low in 2025

March 28, 2026